MegaRobo raises $200 million to expand automated laboratories

Executive Briefing
“MegaRobo announced $200 million in new funding to invest in its core technology and expand...”
Key Takeaways
- 1.MegaRobo said it raised $200 million to invest in core technology and expand its automated life sciences infrastructure.
- 2.Founded in 2016, the company builds robots that let AI software conduct physical experiments, as well as precision measurement and inspection tools for manufacturers.
- 3.The article reports that MegaRobo has raised $600 million across multiple rounds, including nearly $300 million in a 2022 Series C round.
- 4.MegaRobo describes Megalaxy Lab as a platform where researchers and AI agents can configure experiments, send them to automated laboratory systems and receive structured results for the next research cycle.
- 5.The company said it is working with Tencent Cloud and Twist Bioscience on the Poreva Open protein-design challenge. Under the stated plan, Megalaxy will provide laboratory validation for more than 10,000 protein-design sequences.
MegaRobo announced $200 million in new funding to invest in its core technology and expand automated life sciences infrastructure. The company builds robotic systems that allow AI software to run physical experiments.
Financial Context & Deal Developments
MegaRobo said it raised $200 million to invest in core technology and expand its automated life sciences infrastructure.
Founded in 2016, the company builds robots that let AI software conduct physical experiments, as well as precision measurement and inspection tools for manufacturers.
The article reports that MegaRobo has raised $600 million across multiple rounds, including nearly $300 million in a 2022 Series C round.
MegaRobo describes Megalaxy Lab as a platform where researchers and AI agents can configure experiments, send them to automated laboratory systems and receive structured results for the next research cycle.
The company said it is working with Tencent Cloud and Twist Bioscience on the Poreva Open protein-design challenge. Under the stated plan, Megalaxy will provide laboratory validation for more than 10,000 protein-design sequences.
Market Impact & Financial Analysis
If Megalaxy works as described, machine-readable experimental results could help models plan subsequent tests without manual data re-entry.
The plan to test more than 10,000 protein sequences could put model-generated designs against laboratory data. That figure describes intended validation volume, not a count of successful designs.
Market Outlook & Key Factors to Watch
The funding terms and the amount allocated to each investment area are not specified.
The supplied account gives neither protein-validation results nor measured performance figures for Megalaxy.







